Biblio

Author Title Type [ Year

]

Filters: Author is Keyvanfar, Keyvan [Clear All Filters]

2018

Jain, P., Tian, X., Cordes, S., Chen, J., Cantilena, C.R., Bradley, C., Panjwani, R., Chinian, F., Keyvanfar, K., Battiwalla, M., et al. (2018). Over-expression of PD-1 does not predict leukemic relapse after allogeneic stem cell transplantation.Biol Blood Marrow Transplant.

2016

Dumitriu, B., Ito, S., Feng, X., Stephens, N., Yunce, M., Kajigaya, S., Melenhorst, J.J., Rios, O., Scheinberg, P., Chinian, F., et al. (2016). Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.Lancet Haematol3, e22-e29.

Zhao, X., Tian, X., Kajigaya, S., Cantilena, C.R., Strickland, S., Savani, B.N., Mohan, S., Feng, X., Keyvanfar, K., Dunavin, N., et al. (2016). Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.Br J Haematol.

2014

Ito, S., A Barrett, J., Dutra, A., Pak, E., Miner, S., Keyvanfar, K., Hensel, N.F., Rezvani, K., Muranski, P., Liu, P., et al. (2014). Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.Stem Cell Res14, 95-104.